NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer
NuCana plc - American Depositary Shares (NCNA)
Last nucana plc - american depositary shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/ncna/historical
Company Research
Source: GlobeNewswire
EDINBURGH, United Kingdom, Jan. 19, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced interim results today from the ABC-08 Study at the 2018 ASCO Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco, CA. This analysis of the Phase 1b multi-center, open-label study showed that Acelarin, when combined with cisplatin, achieved high response rates and was well-tolerated in front-line advanced biliary tract cancer. Eight patients with advanced biliary tract cancer received Acelarin (625mg/m2) and cisplatin (25mg/m2) on days one and eight of a three-week cycle. A Complete Radiological Response was achieved in one patient, a Partial Response in three patients, and Stable Disease in one patient, resulting in an Objective Response Rate of 50% and a Disease Control Rate of 63% on an intent-to-treat basis. Additionally, the one patient with Stable Disease, whose cancer initially had been considered unsuitable for surgical resection, went on to have surgery to remove the
Show less
Read more
Impact Snapshot
Event Time:
NCNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NCNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NCNA alerts
High impacting NuCana plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NCNA
News
- NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study [Yahoo! Finance]Yahoo! Finance
- NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyGlobeNewswire
- NuCana plc (NASDAQ: NCNA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $4.00 price target on the stock.MarketBeat
- NuCana Announces Plan to Implement ADS Ratio Change [Yahoo! Finance]Yahoo! Finance
- NuCana Announces Plan to Implement ADS Ratio ChangeGlobeNewswire
NCNA
Sec Filings
- 4/9/24 - Form 6-K
- 3/27/24 - Form F-6
- 3/27/24 - Form 424B5
- NCNA's page on the SEC website